Floatz logo

Dapagliflozin

Cancer of the Pancreas

Washington University School of MedicineSmall moleculePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

5 Active assets in the Cancer of the Pancreas cohort.

Asset / SponsorPhaseRating
Avutometinib
Washington University School of Medicine
Phase 2B
Pioglitazone
University of Texas Southwestern Medical Center
Phase 2B
Polyiclc
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1CCC
CDX 1140
Washington University School of Medicine
Phase 2CCC
flt3 ligand
Washington University School of Medicine
Phase 2CCC
Zunsemetinib
Washington University School of Medicine
Phase 1CC
Pidilizumab
Augusta University
Phase 2CC
Hucart-Meso Cells
University of Pennsylvania
Phase 1C

Same molecule, other indications

Dapagliflozin is also rated in:

type 2 diabetes mellitusDormant
BBB
Indicative ·
78 / 100
View asset →
metabolic dysfunction-associated steatotic liver diseaseDormant
BBB
Indicative ·
77 / 100
View asset →
arteriosclerosis disorderDormant
BBB
Indicative ·
73 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →